Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Venetoclax - AbbVie/Genentech

Drug Profile

Venetoclax - AbbVie/Genentech

Alternative Names: A-1195425.0; ABT 0199; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO; Venclyxto

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
  • Developer AbbVie; Celgene Corporation; Dana-Farber Cancer Institute; Eli Lilly and Company; Emory University; Genentech; Janssen Research & Development; M. D. Anderson Cancer Center; Merck & Co; Nantes University Hospital; National Cancer Institute (USA); Nordic Lymphoma Group; Pharmacyclics; Roche; Syros Pharmaceuticals; University Health Network
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Registered Acute myeloid leukaemia
  • Phase III Mantle-cell lymphoma; Myelodysplastic syndromes
  • Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Phase I/II Chronic myelomonocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
  • Phase I B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Cancer; Haematological malignancies; Non-small cell lung cancer; Small cell lung cancer
  • No development reported Systemic lupus erythematosus

Most Recent Events

  • 24 May 2024 AbbVie plans a phase IIB/III trial for Chronic lymphocytic leukemia (First-line therapy, Combination therapy) in unknown location (PO, Tablet) (NCT06428019)
  • 21 May 2024 Hoffmann-La Roche completes a phase I trial in Diffuse large B cell lymphoma (First line therapy, Combination therapy) in the US, France, Italy and Spain (PO) (NCT04790903)
  • 15 Feb 2024 Discontinued - Phase-I for Myelodysplastic syndromes (Combination therapy, Newly diagnosed, Second-line therapy or greater) in Australia (PO) (Roche pipeline, February 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top